News & Updates
Showing Oncology articles
Showing
Tislelizumab improves survival in advanced gastric/gastro-oesophageal junction adenocarcinoma
First-line treatment with tislelizumab plus chemotherapy for advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma yields better overall survival and an acceptable safety profile compared with chemotherapy plus placebo in patients with a programmed death-ligand 1 (PD-L1) tumour area positivity (TAP) score of ≥5 percent, a study has shown.
Testosterone therapy in women may lower risks of MACE, breast cancer
Women on testosterone therapy (TTh) show a lower risk of major adverse cardiac events (MACE) than matched controls, while postmenopausal women have a comparable MACE risk and a similar or significantly reduced risk of breast cancer on age-based subanalysis, reports a study.
Arginine depletion plus chemo ups survival in rare lung cancer
In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.
Thyroid cancer patients with a history of breast cancer enjoy survival benefits
A history of breast cancer (BC) appears protective against mortality in patients with thyroid cancer (TC), suggests a study. This benefit is most pronounced with papillary TC (PTC) in patients who had TC first before BC (TC-1st patients), especially in those with a history of ER-positive BC.
MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133
Interim results of the Italian, multicentre, open-label, phase IIIb MAURIS trial in “real-world” patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) show similar safety and efficacy to those achieved by atezolizumab plus carboplatin and etoposide in the pivotal, phase I/III IMpower133 trial.